Dr. Hartmut Ehrlich, CEO of Abivax discusses the exciting new progress that this French biotechnology company has observed in clinical trials of their most advanced clinical drug candidate, ABX464.  Originally designed to treat HIV by reducing the viral reservoir, Abivax determined the molecule could also be a game-changing treatment in a variety of inflammatory conditions like ulcerative colitis, Crohn's disease and arthritis. #Abivax #ABVX #HIV #UlcerativeColitis #UC #inflammation #IBD Abivax.com